For research use only. Not for therapeutic Use.
BS-181(Cat No.:I000382)is a selective inhibitor of the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2), which is implicated in cardiovascular diseases and inflammation. By inhibiting Lp-PLA2, BS-181 reduces the formation of pro-inflammatory mediators and may improve cardiovascular health. This compound has demonstrated anti-inflammatory and lipid-modulating effects, making it a candidate for treating conditions related to atherosclerosis and other vascular diseases. BS-181 has undergone preclinical and clinical evaluations, showing potential in improving lipid profiles and reducing the risk of cardiovascular events, thereby contributing to the development of novel therapeutic strategies in cardiology.
Catalog Number | I000382 |
CAS Number | 1092443-52-1 |
Synonyms | 5-N-(6-aminohexyl)-7-N-benzyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidine-5,7-diamine |
Molecular Formula | C22H32N6 |
Purity | ≥95% |
Target | Cyclin-Dependent Kinases |
Solubility | DMSO ≥80mg/mL Water ≥2.8mg/mL Ethanol ≥9mg/mL |
Storage | Store at -20°C |
IC50 | 21 nM |
IUPAC Name | 5-N-(6-aminohexyl)-7-N-benzyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidine-5,7-diamine |
InChI | InChI=1S/C22H32N6/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27) |
InChIKey | DNYBIOICMDTDAP-UHFFFAOYSA-N |
SMILES | CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NCCCCCCN |
Reference | <p style=/line-height:25px/> |